Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide
- Correlated keywords
- 486424-21-9 GSK3? inhibitor anabolic glycogen synthase kinase-3? osteogenesis Alzheimer’s disease tau phosphorylating bone formation mineralization Wnt ?-catenin stem cell related research inhibit biochemical GSK3? phosphorylate protein AZD2858 pyrazine analog blood brain barrier phosphorylation in vitro mass activation rats mesenchymal osteoblast differentiation
- Product Overview:
Glycogen synthase kinase 3? (GSK3?) was originally identified for its ability to constitutively phosphorylate and inactivate glycogen synthase, preventing glycogen synthesis.{19045} It can also phosphorylate proteins that are relevant to osteogenesis and Alzheimer’s disease, the latter for which it has earned the moniker, tau phosphorylating kinase.{25567,25565,25566} AZD 2858 is a pyrazine analog that inhibits GSK3? with a Ki value of 4.9 nM.{27205} It crosses the blood brain barrier and inhibits tau phosphorylation in vitro with an IC50 value of 76 nM.{27205} AZD 2858 has also been shown to increase bone mass (via Wnt activation) in rats after a two-week treatment with a maximum effective oral dose of 20 mg/kg once daily.{27203} Furthermore, by inhibiting GSK3?, AZD 2858 can stabilize ?-catenin in rat mesenchymal stem cells (EC50 = 234 nM), spurring osteoblast differentiation.{27204}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.